You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSaprisartan
Accession NumberDB01347
TypeSmall Molecule
GroupsExperimental
DescriptionSaprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure. The mode of (functional) AT1 receptor antagonism has been characterized as insurmountable/noncompetitive for saprisartan. It is very likely that slow dissociation kinetics from the AT1 receptor underlie insurmountable antagonism [1].
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Saprisartan potassium
146613-90-3
Thumb
  • InChI Key: IASZJGRIPLTJMA-UHFFFAOYSA-N
  • Monoisotopic Mass: 648.005605
  • Average Mass: 649.52
DBSALT001863
Categories
UNIIHS64NG1G69
CAS number146623-69-0
WeightAverage: 611.431
Monoisotopic: 610.049723164
Chemical FormulaC25H22BrF3N4O4S
InChI KeyDUEWVPTZCSAMNB-UHFFFAOYSA-N
InChI
InChI=1S/C25H22BrF3N4O4S/c1-2-19-31-21(14-8-9-14)22(24(30)34)33(19)12-13-7-10-18-16(11-13)20(26)23(37-18)15-5-3-4-6-17(15)32-38(35,36)25(27,28)29/h3-7,10-11,14,32H,2,8-9,12H2,1H3,(H2,30,34)
IUPAC Name
1-{[3-bromo-2-(2-trifluoromethanesulfonamidophenyl)-1-benzofuran-5-yl]methyl}-4-cyclopropyl-2-ethyl-1H-imidazole-5-carboxamide
SMILES
CCC1=NC(C2CC2)=C(N1CC1=CC2=C(OC(=C2Br)C2=CC=CC=C2NS(=O)(=O)C(F)(F)F)C=C1)C(N)=O
Pharmacology
IndicationSaprisartan is used in the treatment of hypertension and heart failure.
Structured Indications Not Available
PharmacodynamicsBy inhibiting the angiotensin II receptor, this drug leades to a decrease in sodium reabsorption and a decrease in vasoconstriction. This has the combined effect of decreasing blood pressure.
Mechanism of actionSaprisartan is a selective, potent, orally active and long-acting nonpeptide Angiotensin II type 1 (AT1) receptor antagonist. Saprisartan blocks the renin-angiotensin-aldosterone system (RAAS) at the level of the AT1 receptor that mediates most, if not all, of the important actions of Ang II. Saprisartan binds reversibly to the AT1 receptors in vascular smooth muscle and the adrenal gland. As angiotensin II is a vasoconstrictor, which also stimulates the synthesis and release of aldosterone, blockage of its effects results in decreases in systemic vascular resistance. AT1 receptor antagonists avoid the nonspecificity of the Ang I converting enzyme (ACE) inhibitors.
TargetKindPharmacological actionActionsOrganismUniProt ID
Type-1 angiotensin II receptorProteinyes
antagonist
HumanP30556 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Saprisartan.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Saprisartan.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Saprisartan is combined with Aceclofenac.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Saprisartan is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Adapalene.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Saprisartan.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Saprisartan.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Saprisartan.Approved, Withdrawn
AmbrisentanSaprisartan may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineSaprisartan may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideSaprisartan may increase the hyperkalemic activities of Amiloride.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Saprisartan.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Antipyrine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Saprisartan is combined with Apremilast.Approved, Investigational
ArdeparinArdeparin may increase the hyperkalemic activities of Saprisartan.Approved, Withdrawn
AtenololAtenolol may increase the hypotensive activities of Saprisartan.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Azelastine.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Saprisartan is combined with Balsalazide.Approved, Investigational
BemiparinBemiparin may increase the hyperkalemic activities of Saprisartan.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Benazepril.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Saprisartan.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Saprisartan.Withdrawn
BenoxaprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Benoxaprofen.Withdrawn
BepridilBepridil may increase the hypotensive activities of Saprisartan.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Saprisartan.Approved
BethanidineBethanidine may increase the hypotensive activities of Saprisartan.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Saprisartan is combined with Betulinic Acid.Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Saprisartan.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Saprisartan.Approved
BosentanBosentan may increase the hypotensive activities of Saprisartan.Approved, Investigational
BretyliumBretylium may increase the hypotensive activities of Saprisartan.Approved
BrimonidineBrimonidine may increase the hypotensive activities of Saprisartan.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Saprisartan.Approved
BromfenacThe risk or severity of adverse effects can be increased when Saprisartan is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Bucillamine.Investigational
BupranololSaprisartan may increase the hypotensive activities of Bupranolol.Approved
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Saprisartan.Approved
CandesartanCandesartan may increase the hypotensive activities of Saprisartan.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Captopril.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Saprisartan.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Saprisartan.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Saprisartan.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Saprisartan is combined with Celecoxib.Approved, Investigational
CeliprololSaprisartan may increase the hypotensive activities of Celiprolol.Approved, Investigational
CertoparinCertoparin may increase the hyperkalemic activities of Saprisartan.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Saprisartan.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Saprisartan.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Cilazapril.Approved
CiprofloxacinSaprisartan may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
ClonidineClonidine may increase the hypotensive activities of Saprisartan.Approved
ClonixinThe risk or severity of adverse effects can be increased when Saprisartan is combined with Clonixin.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Saprisartan.Approved
CurcuminThe risk or severity of adverse effects can be increased when Saprisartan is combined with Curcumin.Investigational
CyclosporineSaprisartan may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Saprisartan.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Saprisartan is combined with D-Limonene.Investigational
DalteparinDalteparin may increase the hyperkalemic activities of Saprisartan.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Saprisartan.Investigational
DebrisoquinSaprisartan may increase the hypotensive activities of Debrisoquin.Approved
DeserpidineSaprisartan may increase the hypotensive activities of Deserpidine.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Saprisartan.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Saprisartan is combined with Diclofenac.Approved, Vet Approved
DiflunisalThe risk or severity of adverse effects can be increased when Saprisartan is combined with Diflunisal.Approved
DihydralazineSaprisartan may increase the hypotensive activities of Dihydralazine.Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Saprisartan.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Saprisartan.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Saprisartan.Approved
DrospirenoneSaprisartan may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Saprisartan is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Saprisartan is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Saprisartan is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Ebselen.Investigational
EfonidipineSaprisartan may increase the hypotensive activities of Efonidipine.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Saprisartan is combined with Enalaprilat.Approved
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Saprisartan.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Saprisartan is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Saprisartan.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Saprisartan.Approved
EprosartanEprosartan may increase the hypotensive activities of Saprisartan.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Saprisartan is combined with Etanercept.Approved, Investigational
EtodolacThe risk or severity of adverse effects can be increased when Saprisartan is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Saprisartan is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Saprisartan is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Saprisartan is combined with exisulind.Investigational
FelodipineFelodipine may increase the hypotensive activities of Saprisartan.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Saprisartan.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Fenoprofen.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Saprisartan is combined with Flunixin.Vet Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Flurbiprofen.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Fosinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Saprisartan.Approved, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Saprisartan.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Saprisartan.Approved
GuanethidineGuanethidine may increase the hypotensive activities of Saprisartan.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Saprisartan.Approved, Investigational
HeparinHeparin may increase the hyperkalemic activities of Saprisartan.Approved, Investigational
HexamethoniumSaprisartan may increase the hypotensive activities of Hexamethonium.Experimental
HigenamineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Higenamine.Investigational
HMPL-004The risk or severity of adverse effects can be increased when Saprisartan is combined with HMPL-004.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Saprisartan.Approved
HydralazineHydralazine may increase the hypotensive activities of Saprisartan.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Saprisartan.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Saprisartan.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Saprisartan is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Saprisartan is combined with Icatibant.Approved
IloprostIloprost may increase the hypotensive activities of Saprisartan.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Imidapril.Investigational
IndapamideIndapamide may increase the hypotensive activities of Saprisartan.Approved
IndenololSaprisartan may increase the hypotensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Saprisartan is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Indoprofen.Withdrawn
IndoraminSaprisartan may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Saprisartan.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Saprisartan.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Saprisartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Saprisartan.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Saprisartan is combined with Isoxicam.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Saprisartan.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Kebuzone.Experimental
KetanserinSaprisartan may increase the hypotensive activities of Ketanserin.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Saprisartan is combined with Ketorolac.Approved
LabetalolLabetalol may increase the hypotensive activities of Saprisartan.Approved
LacidipineSaprisartan may increase the hypotensive activities of Lacidipine.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Saprisartan.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Saprisartan is combined with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Saprisartan.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Saprisartan.Approved
LofexidineSaprisartan may increase the hypotensive activities of Lofexidine.Approved, Investigational
LornoxicamThe risk or severity of adverse effects can be increased when Saprisartan is combined with Lornoxicam.Approved
LosartanLosartan may increase the hypotensive activities of Saprisartan.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Loxoprofen.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Saprisartan is combined with Lumiracoxib.Approved, Investigational
MacitentanSaprisartan may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Saprisartan is combined with Magnesium salicylate.Approved
ManidipineSaprisartan may increase the hypotensive activities of Manidipine.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Saprisartan is combined with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Saprisartan.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Saprisartan.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Saprisartan is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Saprisartan is combined with Meloxicam.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Saprisartan is combined with Metamizole.Withdrawn
MethyldopaMethyldopa may increase the hypotensive activities of Saprisartan.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Saprisartan.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Saprisartan.Approved, Investigational
MetipranololMetipranolol may increase the hypotensive activities of Saprisartan.Approved
MetolazoneMetolazone may increase the hypotensive activities of Saprisartan.Approved
MetoprololMetoprolol may increase the hypotensive activities of Saprisartan.Approved, Investigational
MetyrosineSaprisartan may increase the hypotensive activities of Metyrosine.Approved
MibefradilSaprisartan may increase the hypotensive activities of Mibefradil.Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Saprisartan.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Saprisartan.Approved
MizoribineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Saprisartan.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Saprisartan.Approved
MoxonidineSaprisartan may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Nabumetone.Approved
NadololNadolol may increase the hypotensive activities of Saprisartan.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Saprisartan.Approved
NafamostatThe risk or severity of adverse effects can be increased when Saprisartan is combined with Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Naftifine.Approved
NaftopidilSaprisartan may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Naproxen.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when Saprisartan is combined with NCX 4016.Investigational
NebivololSaprisartan may increase the hypotensive activities of Nebivolol.Approved, Investigational
NepafenacThe risk or severity of adverse effects can be increased when Saprisartan is combined with Nepafenac.Approved
NialamideNialamide may increase the hypotensive activities of Saprisartan.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Saprisartan.Approved
NicorandilNicorandil may increase the hyperkalemic activities of Saprisartan.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Saprisartan is combined with Niflumic Acid.Approved
NiguldipineSaprisartan may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineSaprisartan may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Saprisartan is combined with Nimesulide.Approved, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Saprisartan.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Saprisartan.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Saprisartan.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Saprisartan is combined with Nitroaspirin.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Saprisartan.Approved
ObinutuzumabSaprisartan may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Saprisartan.Withdrawn
OlmesartanOlmesartan may increase the hypotensive activities of Saprisartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Olsalazine.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Saprisartan is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Saprisartan is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Saprisartan is combined with Oxaprozin.Approved
OxprenololSaprisartan may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Oxyphenbutazone.Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Saprisartan is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Saprisartan.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Saprisartan.Approved
PenbutololSaprisartan may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentoliniumPentolinium may increase the hypotensive activities of Saprisartan.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Saprisartan.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Saprisartan.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Saprisartan.Withdrawn
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Saprisartan.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Saprisartan.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Saprisartan.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Saprisartan is combined with Pimecrolimus.Approved, Investigational
PinacidilSaprisartan may increase the hypotensive activities of Pinacidil.Withdrawn
PindololPindolol may increase the hypotensive activities of Saprisartan.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Saprisartan.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Saprisartan is combined with Piroxicam.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Saprisartan.Withdrawn
PolythiazidePolythiazide may increase the hypotensive activities of Saprisartan.Approved
PrazosinPrazosin may increase the hypotensive activities of Saprisartan.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Saprisartan is combined with Propacetamol.Approved
PropranololPropranolol may increase the hypotensive activities of Saprisartan.Approved, Investigational
PTC299The risk or severity of adverse effects can be increased when Saprisartan is combined with PTC299.Investigational
QuinaprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Saprisartan.Approved
RamiprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Ramipril.Approved
RasagilineRasagiline may increase the hypotensive activities of Saprisartan.Approved
RemikirenRemikiren may increase the hypotensive activities of Saprisartan.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Saprisartan.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Saprisartan is combined with Resveratrol.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Saprisartan.Approved
RilmenidineSaprisartan may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatSaprisartan may increase the hypotensive activities of Riociguat.Approved
RituximabSaprisartan may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Saprisartan is combined with Rofecoxib.Investigational, Withdrawn
SafrazineSafrazine may increase the hypotensive activities of Saprisartan.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Saprisartan is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Saprisartan is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Saprisartan is combined with Salsalate.Approved
SelegilineSelegiline may increase the hypotensive activities of Saprisartan.Approved, Investigational, Vet Approved
SelexipagSaprisartan may increase the hypotensive activities of Selexipag.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Saprisartan is combined with Seratrodast.Approved, Investigational
SildenafilSildenafil may increase the antihypertensive activities of Saprisartan.Approved, Investigational
SitaxentanSaprisartan may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Spirapril.Approved
SpironolactoneSaprisartan may increase the hyperkalemic activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Saprisartan is combined with SRT501.Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Saprisartan is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Suprofen.Approved, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Saprisartan.Approved, Investigational
TelmisartanTelmisartan may increase the hypotensive activities of Saprisartan.Approved, Investigational
TemocaprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Temocapril.Experimental, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Saprisartan is combined with Teriflunomide.Approved
TerlipressinSaprisartan may increase the hypotensive activities of Terlipressin.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tiaprofenic acid.Approved
TiboloneSaprisartan may increase the hypotensive activities of Tibolone.Approved
TicrynafenSaprisartan may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Saprisartan.Approved
TinoridineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Saprisartan.Approved
TolazolineTolazoline may increase the hypotensive activities of Saprisartan.Approved, Vet Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Saprisartan.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Saprisartan.Approved
TorasemideTorasemide may increase the hypotensive activities of Saprisartan.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Saprisartan.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Saprisartan.Approved
TravoprostTravoprost may increase the hypotensive activities of Saprisartan.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Saprisartan.Approved, Investigational
TriamtereneSaprisartan may increase the hyperkalemic activities of Triamterene.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Saprisartan.Approved, Vet Approved
TrimazosinSaprisartan may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Saprisartan.Approved
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Saprisartan.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Trisalicylate-choline.Approved
UdenafilUdenafil may increase the antihypertensive activities of Saprisartan.Approved, Investigational
UnoprostoneSaprisartan may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Saprisartan is combined with Valdecoxib.Investigational, Withdrawn
ValsartanValsartan may increase the hypotensive activities of Saprisartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Saprisartan.Approved
VinpocetineSaprisartan may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineSaprisartan may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Saprisartan.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Saprisartan is combined with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Saprisartan is combined with Zomepirac.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Timmermans PB: Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol. 1999 Nov;15 Suppl F:26F-8F. [PubMed:10579749 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.647
Caco-2 permeable-0.6148
P-glycoprotein substrateSubstrate0.5611
P-glycoprotein inhibitor INon-inhibitor0.6454
P-glycoprotein inhibitor IINon-inhibitor0.5279
Renal organic cation transporterNon-inhibitor0.8625
CYP450 2C9 substrateNon-substrate0.653
CYP450 2D6 substrateNon-substrate0.7866
CYP450 3A4 substrateSubstrate0.5105
CYP450 1A2 substrateNon-inhibitor0.6561
CYP450 2C9 inhibitorInhibitor0.6267
CYP450 2D6 inhibitorNon-inhibitor0.7996
CYP450 2C19 inhibitorInhibitor0.5274
CYP450 3A4 inhibitorNon-inhibitor0.5167
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8837
Ames testNon AMES toxic0.5853
CarcinogenicityNon-carcinogens0.6378
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5781 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9673
hERG inhibition (predictor II)Inhibitor0.6568
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0151 mg/mLALOGPS
logP5.89ALOGPS
logP3.35ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)2.27ChemAxon
pKa (Strongest Basic)5.18ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area120.22 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity137.15 m3·mol-1ChemAxon
Polarizability54.2 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 2-arylbenzofuran flavonoids. These are phenylpropanoids containing the 2-phenylbenzofuran moiety.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
Class2-arylbenzofuran flavonoids
Sub ClassNot Available
Direct Parent2-arylbenzofuran flavonoids
Alternative Parents
Substituents
  • 2-arylbenzofuran flavonoid
  • Phenylbenzofuran
  • 2-phenylbenzofuran
  • Sulfanilide
  • Benzofuran
  • 1,2,4,5-tetrasubstituted imidazole
  • Benzenoid
  • N-substituted imidazole
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl bromide
  • Heteroaromatic compound
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Imidazole
  • Furan
  • Cyclic alcohol
  • Azole
  • Trihalomethane
  • Primary carboxylic acid amide
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Halomethane
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organobromide
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name:
AGTR1
Uniprot ID:
P30556
Molecular Weight:
41060.53 Da
References
  1. Timmermans PB: Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol. 1999 Nov;15 Suppl F:26F-8F. [PubMed:10579749 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 30, 2007 12:15 / Updated on October 14, 2016 13:11